Preventing strokes in children with sickle cell anemia in Nigeria
Stroke Prevention in Nigeria: SPRING 2
This study is looking at how well hydroxyurea can help prevent strokes in children with sickle cell anemia in Nigeria, and it's for kids who might be at risk due to their blood flow.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-10994102 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of hydroxyurea therapy for preventing strokes in children with sickle cell anemia living in Nigeria. It builds on previous findings from a randomized controlled trial that compared different doses of hydroxyurea and their impact on stroke incidence and hospitalizations. The study will involve multiple centers and aims to confirm that hydroxyurea can effectively reduce stroke risk in children with abnormal blood flow velocities. Participants will be monitored for stroke events and other health outcomes over the course of the trial.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-21 years diagnosed with sickle cell anemia and exhibiting abnormal transcranial Doppler velocities.
Not a fit: Patients who do not have sickle cell anemia or those without abnormal transcranial Doppler velocities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of strokes in children with sickle cell anemia, improving their overall health and quality of life.
How similar studies have performed: Previous studies have shown promising results with hydroxyurea therapy in reducing stroke risk in similar populations, indicating that this approach has potential for success.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Debaun, Michael R. — Vanderbilt University Medical Center
- Study coordinator: Debaun, Michael R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.